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Background: The aim of the paper is to investigate the outcomes of patients younger than 55 years in
Victoria, Australia undergoing radical prostatectomy (RP) for prostate cancer.
Materials and methods: Data on all men undergoing RP in Victoria between January 1, 2004 and
December 31, 2014 were obtained from the Victorian Cancer Registry. Tumor characteristics including
Gleason grade, stage of disease (based on ﬁnal pathology specimen), and cause of death were also ob-
tained. Statistical analysis was performed using Chi-square test, Cox proportional hazards method, and
Kaplan-Meier analysis.
Results: A total of 14,686 men underwent RP during the deﬁned period. Of these men 109 were aged 35
e44 years and 1,998 were aged 45e54 years. Men aged 35e44 years and 45e54 years were compared
against men aged 55e74 years. The majority of men between the ages of 35 years and 44 years, and
45 years and 54 years had higher rates of Gleason  7 disease compared with men aged between
55 years and 74 years (92.7% vs. 86.8% vs. 79.3%; P < 0.01) and  T2 disease (82.6% vs. 75.6% vs. 49.9%;
P < 0.01) but similar median prostate-speciﬁc antigen values. On a multivariate analysis adjusting for
Gleason score, T stage, and prostate-speciﬁc antigen, men aged 45e54 years and 55e64 years had 67%
and 46% increase in overall survival, respectively, compared to men aged 65e74 years; but these dif-
ferences were not seen in the 35e44 year age group. There were no differences in prostate cancer speciﬁc
deaths between the groups. The 5- and 10-year overall survival outcomes were both higher for men aged
45e54 years compared to mean aged 55e74 years (97.9% vs. 95.9% and 94.9% vs. 85.3).
Conclusion: Men aged 45e54 years undergoing RP had better overall survival compared to men aged 55
e74 years, but these effects were not seen in men aged 35e44 years. There were no differences in
prostate cancer speciﬁc survival in these groups.
© 2017 Asian Paciﬁc Prostate Society, Published by Elsevier Korea LLC. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer remains the most common non skin malignancy
diagnosed in Australian men, accounting for 25.2% of all new can-
cers diagnosed in men in 2016 and is the third leading cause of
fatality from cancer.1 On a global scale, Australia ranks ﬁfth of 15
countries in prostate cancer incidence, and the incidence ofool, Level 2, 5 Arnold St, Box
ngupta).
te Society, Published by Elsevierprostate cancer has been increasing.2,3 The highest age-speciﬁc
incidence occurs in men aged 65e69 years, with the incidence of
prostate cancer increasing exponentially from 35 years of age
onwards.1
Guidelines generally advocate screening be performed in men
with at least a 10-year life expectancy.4,5 In this regard, prostate
cancer screening in younger men has potential to prevent prostate
cancer deaths. Further, younger men are more likely to be
amenable to aggressive treatment with a curative intent than those
in an older age group owing to fewer comorbidities. However, most
screening guidelines exist for men 50 years of age and older andKorea LLC. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 6 (2018) 31e3532prostate cancer screening is generally not routinely considered
from 35 years of age, where incidence of the cancer ﬁrst becomes
notable.1
It has been shown that men older than 75 years have higher
grades of disease and that age is an independent risk factor for
poorer prostate cancer speciﬁc survival.6e8 At the same time, it has
been reported in the United States that trends in prostate cancer are
changing to affect a younger demographic.9 However, few studies
have selectively focused on prostate cancer characteristics and
outcomes in younger men, much less in the Australian context.
Therefore, we aimed to investigate the outcomes of men younger
than 55 years undergoing radical prostatectomy (RP) for the
treatment of prostate cancer.2. Materials and methods
2.1. Population characteristics
Victoria is the second largest state in Australia, with one fourth
of the country's males at about 2,484,490 men. Data was obtained
from the Victorian Cancer Registry, which receives mandatory
cancer diagnosis notiﬁcations from 240 hospitals and pathology
laboratories. The data includes patient demographics and detailed
histopathological information.
Data on all men undergoing RP in Victoria between January 1,
2004 and December 31, 2014 were obtained from the Victorian
Cancer Registry. Tumor characteristics including Gleason grade,
stage of disease (based on histopathological examination and
spread of tumor), and cause of death were acquired.2.2. Statistical analyses
Chi-squared tests were used to compare patient and tumor
characteristics. Univariate and multivariate survival analysis was
performed using Kaplan-Meier survival curves and Cox-
proportional hazard methods. Version 17.0 of the SPSS statistical
software (SPSS Inc., Chicago, IL, USA) was used.2.3. Ethics approval
No ethics approval was required for the data used in this study
as the data included no identifying information. Datawere released
according to Victorian Cancer Registry Data Access Guidelines un-
der a memorandum of understanding including conditions about
data security, use, and destruction.Table 1
Patient characteristics grouped by age.
35e44 yr 45e54 yr
Gleason score
6 51 (46.8) 708 (35.4)
7 50 (45.9) 1,027 (51.4)
8e10 2 (1.8) 130 (6.5)
Unknown 6 (5.5) 133 (6.7)
Stage
T1/T2 90 (82.6) 1,510 (75.6)
T3/4 19 (17.4) 467 (23.4)
Median PSA 6.2 (2.2e14) 6.3 (0.3e75)
Location
Metropolitan 86 (78.9) 1,504 (75.4)
Rural 23 (21.1) 490 (24.6)
Overall deaths 2 47
PC deaths 1 16
NS, not signiﬁcant, PC, prostate cancer; PSA, prostate-speciﬁc antigen.3. Results
A total of 14,686 men underwent RP between January 1, 2004
and December 31, 2014. Of these men, 109 were aged 35e44 years
and 1,998 were aged 45e54 years. Younger men in the 35e44 years
and 45e54 years age groups were compared against older men
aged between 55 years and 74 years. The majority of men between
the ages of 35 years and 44 years, and 45 years and 54 years had
higher rates of Gleason  7 disease compared with men aged be-
tween 55 years and 74 years (92.7% vs. 86.8% vs. 79.3%; P < 0.01)
and  T2 disease (82.6% vs. 75.6% vs. 49.9%; P < 0.01) but similar
median prostate-speciﬁc antigen (PSA) values (Table 1). A higher
proportion of RP was performed in the metropolitan setting
compared to rural, for all age categories.3.1. Outcomes post RP
On a multivariate analysis adjusting for Gleason score, T stage,
and PSA, men aged between 45e54 years and 55e64 years had 67%
and 46% increase in overall survival (Fig. 1), respectively, compared
to men aged 65e74 years (hazard ratio 0.33; 95% conﬁdence in-
terval 0.20e0.56; P < 0.05) and hazard ratio 0.54 (95% conﬁdence
interval 0.41e0.72). However, these differences were not seen in
the 35e44 age group (Table 2). There were no differences in pros-
tate cancer speciﬁc deaths between the groups (Table 3) (Fig. 2).
The 5- and 10-year overall survival and prostate cancer speciﬁc
rates are seen in Table 4.4. Discussion
The differences in pathological and survival data we observed in
males younger than 55 years as compared to those older than
55 years present unique opportunities and challenges. Prostate
cancer is generally considered to be a disease of older men. In the
era of prostate cancer screening, the incidence of prostate cancer
increased nearly sixfold from 5.6 cases per 100,000 person-years to
32 cases per 100,000 person-years (1986e2008 data),10 and
currently over 10% of new diagnoses that occur are in younger men
aged 55 years and below.10,11 Salinas et al12 observed that the
greater proportion of cases diagnosed in those younger than
55 years are clinically localized, however males of a younger de-
mographic are more likely to succumb to their cancer where it is of
higher grade and stage.12 Therefore, this reﬂects a demographic of
males with early onset prostate cancer that is distinct from the
prostate cancer identiﬁed in older males that is beginning to be
further explored.55e64 yr 65e74 yr P
0.00
1,919 (27.4) 968 (18.5)
3,704 (53) 2,949 (56.4)
679 (9.7) 819 (15.7)
689 (9.9) 490 (9.4)
0.00
4,790 (68.5) 3,209 (61.4)
2,131 (30.5) 1,960 (37.5)
6.6 (0.2e95) 6.4 (0.4e96) NS
5,145 (73.7) 3,892 (74.5) NS
1,836 (26.3) 1,329 (25.5)
262 329 e
58 58 e
Fig. 1. KaplaneMeier curve of overall survival of men undergoing radical prostatectomy (RP) by age groups.
Table 2
Univariate and multivariate analysis of overall survival.
Univariate Multivariate
HR (95 CI) P HR (95 CI) P
Age (yr)
65e74 1.0 e 1.0 e
35e44 0.35 (0.09e1.40) 0.13 0.99 (0.24e4.04) 0.99
45e54 0.34 (0.25e0.47) <0.05 0.33 (0.20e0.56) <0.05
55e64 0.52 (0.45e0.62) <0.05 0.54 (0.41e0.72) <0.05
Gleason score
6 1.0 e 1.0 e
7 0.92 (0.76e1.11) 0.37 0.72 (0.51e1.00) 0.05
8e10 2.14 (1.68e2.72) <0.05 1.68 (1.10e2.56) 0.02
Unknown 0.87 (0.67e1.12) 0.28 0.59 (0.38e0.93) 0.02
Stage
T1/T2 1.0 e 1.0 e
T3/T4 1.30 (1.20e1.40) <0.05 1.48 (1.11e1.96) <0.05
PSA 0.98 (0.95e1.0) 0.16 0.98 (0.96e1.0) 0.17
Location
Metropolitan e e 1.0 e
Rural e e 1.4 (1.09e1.89) <0.05
CI, conﬁdence interval; HR, hazard ratio; PSA, prostate-speciﬁc antigen.
Table 3
Univariate and multivariate analysis of prostate cancer speciﬁc survival.
Univariate Multivariate
HR (95 CI) P HR (95 CI) P
Age (yr)
65e74 1.0 e 1.0 e
35e44 1.02 (0.14e7.40) 0.98 3.39 (0.44e25.78) 0.24
45e54 0.66 (0.38e1.15) 0.14 0.58 (0.20e1.68) 0.31
55e64 0.62 (0.45e0.94) <0.05 1.04 (0.60e1.78) 0.90
Gleason score
6 1.0 e 1.0 e
7 1.72 (0.88e3.34) 0.11 0.99 (0.40e2.46) 0.99
8e10 20.56 (11.09e38.11) <0.05 7.76 (3.19e18.90) <0.05
Unknown 2.93 (1.44e5.94) <0.05 1.36 (0.49e3.79) 0.55
Stage
T1/T2 1.0 e 1.0 e
T3/T4 10.39 (6.76e15.96) <0.05 5.45 (2.94e10.10) <0.05
PSA 0.99 (0.9e1.04) 0.73 0.99 (0.94e1.05) 0.82
Location
Metropolitan 1.0 e 1.0 e
Rural 0.94 (0.64e1.39) e 0.74 0.37
CI, conﬁdence interval; HR, hazard ratio; PSA, prostate-speciﬁc antigen.
Tan et al / Survival outcomes of younger men (< 55 years) 33In our analysis, we found that men aged 45e54 years with
prostate cancer had lower grade disease and greater overall sur-
vival than their 55e74-year-old counterparts. This is consistent
with the results of several other studies.13e15 Table 5 summarizes
the results of several recent studies.13,15e18 In particular, a database
study by Kinnear et al15 examined the outcomes of 7,018 men with
prostate cancer in the state of South Australia, and found younger
men had a greater proportion of T stage < 2 disease, lower median
PSA, and higher rates of Gleason score < 7. This provides a good
comparison of data from an interstate cohort.
Interestingly, the survival difference between the age groups
was not observed in the 35e44 age group. A population-based
cohort study by Lin et al17 had similar ﬁndings. They studied theoutcomes of 318,774 men aged 35e74 years with prostate cancer,
and found that among all age groups with high grade and stage, the
youngest men (aged 35e44 years) were at the highest risk of all-
cause and cancer-speciﬁc death.17 Similarly, Thorstenson et al19
found a strong association between younger age and poor prog-
nosis in men in whom metastatic disease was diagnosed before
they were aged 50e55 years. This adds to the growing body of
evidence of worse prognosis in the youngest group of men with
prostate cancer.12 This prompts the theory that early onset prostate
cancer may potentially be biologically different from cancer seen in
older men.19
There are threewell-recognized risk factors for prostate cancer:
family history, age, and race. Family history is a risk factor of
Table 4
Five- and 10-year survival rates of men undergoing radical
prostatectomies.
Overall survival 5-year 10-year
35e44 96.9 96.9
45e54 97.9 94.9
55e64 96.9 90.7
65e74 94.5 84.0
PC survival
35e44 97.9 97.9
45e54 99.3 98.1
55e64 99.4 97.6
65e74 99.0 96.9
PC, prostate cancer.
Fig. 2. KaplaneMeier curve of prostate cancer speciﬁc survival of men undergoing radical prostatectomy (RP) by age groups.
Prostate Int 6 (2018) 31e3534particular relevance to the discussion. Even though family history
is responsible for a mere 9% of cases, early onset prostate cancer is
likely to represent a larger proportion of hereditary disease than
onset later than 55 years20 and has been shown to have a statis-
tically signiﬁcant greater number of alleles associated with
increased risk of prostate cancer.21 Prostate cancer incidence in-
creases with age more than any other form of cancer,22 but as
shown in our results, the age at which the cancer is diagnosed can
confer prognostic signiﬁcance. In a population-based study ofTable 5
Other recent studies of outcomes of younger men undergoing radical prostatectomies.
Study Year No. of patients Age (yr) Overall survival Pros
Freedland et al.13 2004 88 <50 e
Loeb et al.16 2008 55 <40 e
Lin et al.17 2009 30,338 <55 85% (10-yr)
Becker et al.18 2014 175 <50 e
Kinnear et al.15 2016 182 <50 e
PSA, prostate-speciﬁc antigen.1,476 Australian families with prostate cancer, Cui et al23 con-
ducted segregation analyses and found that pattern best ﬁt early
onset prostate cancer was of autosomal dominantly inherited risk.
Ongoing cancer genetics research has identiﬁed single nucleotide
polymorphism in a transcription factor involved in early onset
prostate cancer as well as the allele that is more signiﬁcantly
enhanced in these patients.12 Clearly, genetic inheritance has an
important role in prostate cancer in the younger population.
Further work could provide an opportunity to identify further
genetic loci associated with early-onset disease, as well as explore
the possibility of genetic testing to identify individuals at risk who
may beneﬁt from increased surveillance.
Younger men with biologically signiﬁcant disease are more
likely to undergo radical treatment, as they tend to have more
favorable disease staging amenable to cure and fewer comorbid-
ities.17 Longer life expectancy in these younger patients also means
longer time to deal with possible side effects of treatment. Urinary
incontinence and erectile dysfunction often have a greater impact
on quality of life in the younger cohort. Becker et al18 reported
continence rates of 97.4% in younger patients, and that age was an
independent predictor of continence recovery at 1 year after RP. In
addition, younger men retained more erectile function post-
operatively, as well as favorable recovery of erectile function than
older counterparts after surgery.18 Bilateral intraoperative nerve-tate cancer survival PSA free survival Biochemical recurrence free survival
e 73% (5-yr) e
e e 94.8%
87% (10-yr) e e
e e 63% (10-yr)
98% e e
Tan et al / Survival outcomes of younger men (< 55 years) 35sparing was found to be the most important predictor of post-
operative erectile function recovery.18 These ﬁndings were
corroborated by Labanaris et al.24 In their cohort, 92.6% of patients
< 50 years underwent bilateral nerve-sparing RP, and reported 12-
month continent and potency rates at 95.5% and 97.3%,
respectively.24
There are some limitations to our study. Firstly, this dataset is
representative of only one Australian state, so the applicability of the
results to thewiderpopulation is uncertain but likely to be consistent
given the nationalized health systems. Secondly, data on comorbid-
ities, postoperative complications, and long-term oncological and
functional outcomes were not available. This information would be
particularly pertinent in a young cohort with longer life expectancy.
Finally, like all database studies, our data is hostage to a few con-
founders and bias related to the observational nature of the study.
Overall, prostate cancer in younger males is an important clin-
ical entity. We have shown in the Australian context that there are
signiﬁcant age-related differences in important parameters and
outcomes, and these have been corroborated by numerous other
analyses. Further research is required to ascertain the true health
burden and economic costs of such ﬁndings, and for recommen-
dations to be made particularly with regards to prostate cancer
screening and management guidelines for prostate cancer detec-
tion, diagnosis, and management in the younger male population.
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